Abnormal diastolic function underlies the different beneficial effects of cardiac resynchronization therapy on
Qi Wang1, Kang-Yu Chen1, Fei Yu1
1Department of Cardiology, Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, China.
Insights
Heart failure etiology impacts cardiac resynchronization therapy benefits. Patients with ischemic cardiomyopathy and severe diastolic dysfunction showed poorer responses to CRT, highlighting the role of diastolic function in treatment outcomes.
Area of Science:
- Cardiology
- Heart Failure Research
- Medical Device Technology
Background:
- Cardiac resynchronization therapy (CRT) is a key treatment for heart failure.
- The effectiveness of CRT can vary based on the underlying cause of heart failure.
- Diastolic function's role in CRT outcomes requires further investigation.
Purpose of the Study:
- To explore the association between diastolic function and CRT benefits.
- To compare CRT effects in patients with ischemic versus non-ischemic cardiomyopathy.
- To identify factors influencing CRT response based on heart failure etiology.
Main Methods:
- 104 heart failure patients were categorized into ischemic (n=27) and non-ischemic (n=77) cardiomyopathy groups.
- Left ventricular diastolic function was assessed via echocardiography pre-implantation.
- CRT effects were evaluated at six months using clinical and echocardiographic parameters.
Main Results:
- Ischemic cardiomyopathy patients had more restrictive filling patterns.
- Non-ischemic cardiomyopathy patients demonstrated significantly higher CRT response rates and improved echocardiographic parameters.
- Restrictive filling was identified as an independent factor affecting CRT response.
Conclusions:
- Heart failure etiology significantly influences CRT outcomes.
- Ischemic cardiomyopathy is associated with more severe diastolic dysfunction and reduced CRT benefits.
- Severe diastolic dysfunction in systolic heart failure predicts poor CRT response.
Objectives::
To investigate the association between diastolic function and the different beneficial effects of cardiac resynchronization therapy in patients with heart failure due to different causes.
Methods::
The 104 enrolled patients were divided into an ischemic cardiomyopathy group (n=27) and a non-ischemic cardiomyopathy group (n=77) according to the cause of heart failure. Before implantation, left ventricular diastolic function was evaluated in all patients using echocardiography. After six months of follow-up, the beneficial effects of cardiac resynchronization therapy were evaluated using a combination of clinical symptoms and echocardiography parameters.
Results::
The ischemic cardiomyopathy group included significantly more patients with restrictive filling than the non-ischemic cardiomyopathy group. The response rate after the implantation procedure was significantly higher in the non-ischemic cardiomyopathy group than in the ischemic cardiomyopathy group. Degrees of improvement in echocardiography parameters were significantly greater in the non-ischemic cardiomyopathy group than in the ischemic cardiomyopathy group. Multivariate regression analysis showed that a restrictive filling pattern was an independent factor that influenced responses to cardiac resynchronization therapy.
Conclusions::
This study again confirmed that the etiology of heart failure affects the beneficial effects of cardiac resynchronization therapy and a lower degree of improvement in ventricular systolic function and remodelling was observed in ischemic cardiomyopathy patients than in non-ischemic cardiomyopathy patients. In addition, systolic heart failure patients with severe diastolic dysfunction had poor responses to cardiac resynchronization therapy. Ischemic cardiomyopathy patients exhibited more severe diastolic dysfunction than non-ischemic cardiomyopathy patients, which may be a reason for the reduced beneficial effect of cardiac resynchronization therapy.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology


